Prognostic Value of Oxygen-15 Water PET in Coronary Artery Disease
Key facts
- Who runs it
- Vastra Gotaland Region
- Where
- Sweden1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 40,000 people, planned
- Starts
- Dec 2026
- Expected to end
- Dec 2036
- Type of study
- Interventional
- Treatments tested
- Oxygen-15 Water
- Record updated
- 12 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study evaluates the prognostic value of quantitative myocardial perfusion imaging using oxygen-15 water positron emission tomography in patients with clinically suspected or known coronary artery disease (main basket), and explores temporal changes in myocardial perfusion related to disease progression, underlying pathophysiological processes, or treatment-related effects (additional baskets).
The group in the trial
- Oxygen-15 Water PETTreatment being tested
In the main basket, participants will undergo a single quantitative myocardial perfusion imaging examination using oxygen-15 water PET at rest and during pharmacological stress (adenosine or regadenoson). In the additional baskets, the same examination will be performed twice, at baseline and at follow-up. In all baskets, blood samples will be collected when feasible and stored in a biobank for future research.
Treatment: Oxygen-15 Water
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Prognostic Performance of Quantitative Myocardial Perfusion Imaging Using H2[15O] Positron Emission Tomography in Coronary Artery Disease - The AQUA COR Trial
- Record updated
- 12 November 2026